The role of imatinib in the treatment of pulmonary hypertension

Imatinib mesylate, a receptor tyrosine kinase inhibitor that has been approved for several oncology conditions, is currently under investigation for pulmonary arterial hypertension. The therapeutic rationale is that its targets, platelet-derived growth factor receptor beta (PDGFR-β) and proto-oncoge...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs of Today 2013-03, Vol.49 (3), p.203-211
1. Verfasser:	Mucke, H
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Benzamides - adverse effects Benzamides - pharmacology Benzamides - therapeutic use Clinical Trials as Topic Disease Progression Familial Primary Pulmonary Hypertension Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - physiopathology Imatinib Mesylate Muscle, Smooth, Vascular - cytology Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - metabolism Piperazines - adverse effects Piperazines - pharmacology Piperazines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-kit - antagonists & inhibitors Pyrimidines - adverse effects Pyrimidines - pharmacology Pyrimidines - therapeutic use Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors Receptor, Platelet-Derived Growth Factor beta - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!